Remark:
Poster Session 1 = odd numbers
Poster Session 2 = even numbers
Registration
Welcome reception
Opening
Session Chair
Dr Scott A. BILLER
AGIOS PHARMACEUTICALS, Cambridge, United States
The Metalated Flatland Conduit to New Synthetic Aromatics and Heteroaromatic Chemistry
Prof. Victor SNIECKUS
QUEEN'S UNIVERSITY, Ontario, Canada
C-H Activation: Direct Arylation and Alkenylation of Oxazoles
Dr. Florence MAHUTEAU
INSTITUT CURIE, ORSAY, France
Coffee-break
Orally Active, Brain Penetrant Beta-Secretase (BACE) Inhibitors: Consolidating Property-Based and Structure-Based Drug Design
Dr. Stephen HITCHCOCK
AMGEN INC, Thousand Oaks, United States
From Structures to Systems: Structure Based Design of Therapeutics and Imaging Probes
Dr. Ulrich WENDT
SANOFI AVENTIS, Frankfurt, Germany
Structure-Activity Relationships and Cancer-Cell Selective Toxicity Of Novel Inhibitors of Glioma-Associated Oncogene Homolog 1 (Gli1)-Mediated Transcription
Dr Naoaki FUJII
ST.JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States
Molecular Recognition at the Active Site of Catechol-O-Methyl Transferase (COMT): Energetically Favorable Expulsion of a Single Water Molecule with Novel Bisubstrate Inhibitors.
Mr Manuel ELLERMANN
ETH ZURICH, Zurich, Switzerland
Lunch and Poster Session 1
Bio-Inspired Organocatalysis: From Concepts to Applications in Heterocycle Synthesis
Prof. Magnus RUEPING
RWTH AACHEN, Aachen, Germany
Discovery of Ixempratm (ixabepilone), an Epothilone Analogue for Treatment of Metastatic Breast Cancer
Dr. Gregory VITE
BMS, Princeton, United States
Design and Synthesis of Novel Polyketide Molecular Frameworks to Access Natural Product-Like Protein-Protein Interaction Inhibitors as Novel Chemotherapeutic Agents
Dr Giovanna ZINZALLA
LONDON SCHOOL OF PHARMACY, London, United Kingdom
Coffee-break and Poster Session 1
Compound Collection Enhancement (CCE): Increasing Quality and Size of the AZ Compound Collection
Dr. Kay BRICKMANN
ASTRA ZENECA, Mölndal, Sweden
Approach to the Synthesis of Pycnanthuquinone C by Gold(I)-Catalyzed Cyclization of 1,5-Enynes
Ms NURIA HUGUET
INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA, Tarragona, Spain
C-H: A New Functional Group for Streamlining Synthesis
Prof. Christina WHITE
UNIVERSITY OF ILLINOIS, Urbana, United States
Closing of the day
Session Chair
Dr Edmond DIFFERDING
UCB, Braine-l'Alleud, Belgium
Development and Applications of New Metal-Catalyzed Carbon-Carbon Bond Forming Reactions
Prof. Jonathan A. ELLMAN
UNIVERSITY OF CALIFORNIA, Berkeley, United States
Case Histories of Fragment Based Discovery: from Crystal to Clinic
Dr David REES
ASTEX THERAPEUTICS, Cambridge, United Kingdom
Design and synthesis of polyfluoroalkyl-containing purine isosters and phospha-purines as a potential Adenosine Deaminase (ADA) and Inosine 5’-monophosphate dehydrogenase (IMPDH) inhibitors
Dr Dmytro VOLOCHNYUK
ENAMINE, Kyiv, Ukraine
Coffee-break and Poster Session 1
The Fight against AIDS. The "Old" Reverse Transcriptase (RT) and the "New" DDX3
Prof. Maurizio BOTTA
UNIVERSITY OF SIENA, Siena, Italy
Targeting Protein-Protein Interactions: Bcl-2 Family Protein Inhibitors to Treat Cancer
Dr. Steve ELMORE
ABBOTT LABORATORIES, Abbott Park, United States
Discovery Biology Fueled with Synthetic Chemicals
Prof. Patrick G. HARRAN
UNIVERSITY OF CALIFORNIA, Los Angeles, United States
Lunch & Poster session 1
Afternoon Session: Business Mini-Symposium
Session Chair
Dr Gene VAISBERG
CHEMBRIDGE CORPORATION, San Diego, United States
Compound Screenings in Model Plants to Identify New Agrochemicals: Strengths and Limitations
Dr. Dominique AUDENAERT
GHENT UNIVERSITY, GHENT, Belgium
Creating a medicinal chemistry created screening library
Dr. Peter BEAN
CYTOKINETICS, South San Francisco, United States
Optimization of a Small Molecule Screening Library to support HTS Campaigns Across Diverse Therapeutic Areas and Target Classes
Dr. Andrew.J. GARTON
OSI PHARMACEUTICALS, Framingdale, United States
Strategies Toward The Establishment and Evolution of a CNS Focused Small Molecule Screening Collection
Dr. Kevin HODGETTS
GALENEA, CAMBRIDGE, United States
Small Molecule Screening Libraries in Drug Discovery: Today & Tomorrow
Dr. Duncan JUDD
GLAXOSMITHKLINE, Essex, United Kingdom
JHICC - When Vast Chemical Diversity Meets Ion Channel Targets
Dr Min LI
JOHNS HOPKINS MEDICAL SCHOOL, Baltimore, United States
Coffee-break
Navigating the NIH Roadmap - Building a Screening Collection for Discovery of Biological Probes
Dr. Victor PANCHENKO
BIOFOCUS, San Francisco, United States
Kinase Inhibitors in Compound Collection of Life Chemicals
Dr. Alexander POKHOLENKO
LIFE CHEMICALS, Ukraine
Chemically Validated Combinatorial Approach to Large Libraries of Individual Drug Like Compounds
Dr. Aleksandr SHIVANYUK
MACROCHEM, Kiev, Ukraine
Scaffold-based Libraries: It’s design and applications
Dr. Bernd WENDT
EMBL HEIDELBERG, Heidelberg, Germany
Out-Sourcing Of Small Molecule Screening Libraries: Lessons From The Past, View Into The Future
Dr Gene VAISBERG
CHEMBRIDGE CORPORATION, San Diego, United States
Q & A
Closing of the day
Session Chair
Prof. Valery P. KUKHAR
INSTITUTE OF BIOORGANIC CHEMISTRY AND PETROCHEMISTRY, Kyiv, Ukraine
The Chemistry of DNA Repair and DNA Lesion Tolerance
Prof. Thomas CARELL
LUDWIG-MAXIMILIANS-UNIVERSITY MUNICH, Munich, Germany
Design of BCR-Abl Kinase Inhibitors to Treat Imatinib-Resistant Leukaemia
Dr Paul W. MANLEY
NOVARTIS PHARMA, Basel, Switzerland
SQUIRRELnovo: De Novo Design of a PPARalpha Agonist by Bioisosteric Replacement
Dr Ewgenij PROSCHAK
UNIVERSITÄT FRANKFURT, Frankfurt a. M., Germany
Coffee-break
Discovery of PF-610355: An Inhaled Once-daily Beta-2 Adrenoceptor Agonist for Asthma & COPD
Mr. Paul GLOSSOP
PFIZER GLOBAL R&D, Sandwich Kent, United Kingdom
Discovery of NVP-BEZ235, a New Anti-Cancer Drug Candidate Targeting the PI3K/Akt/mTOR Pathway
Dr. Frédéric STAUFFER
NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Conformational Restriction as a Design Concept for Unnatural Amino Acids
Prof. Igor KOMAROV
KIEV TARAS SHEVCHENKO UNIVERSITY, Kiev, Ukraine
Directed Evolution of Enzymes: New Biocatalysts for Organic Synthesis'
Prof. Nicholas John TURNER
UNIVERSITY OF MANCHESTER, Manchester, United Kingdom
Lunch and Poster Session 2
Free afternoon
Session Chair
Prof. Gerhard ECKER
UNIVERSITY OF VIENNA, Vienna, Austria
A Small Molecule with a Big Impact: Inspirations from Proline Catalysis
Prof. Benjamin LIST
MAX PLANCK INSTITUT, Muelheim an der Ruhr, Germany
The Structure Based Design of Potent, Selective BACE1 Inhibitors as Potential Disease Modifying Treatments for Alzheimer's Disease
Dr Al ROBICHAUD
SAGE, Princeton, United States
Chiral Imidates: A New Class of Nitrogen-Based Chiral Ligands.
Prof. Johan VAN DER EYCKEN
UGENT, Ghent, Belgium
Coffee-break and Poster Session 2
Orexin Receptor Antagonists – A New Therapeutic Principle in CNS Disorders?
Dr Christoph BOSS
ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland
Guanidinium Toxins: Unique Natural Products in both Form and Function
Prof. Justin DU BOIS
STANFORD UNIVERSITY, Stanford, United States
Cation–Pi Interactions in the S4 Pocket of Factor Xa: Dramatic Enhancement upon N-Alkylation of Ammonium Ions
Ms Laura Maria SALONEN
ETH ZURICH, Zurich, Switzerland
Lunch and Poster Session 2
Small Molecule Drug Discovery in the Modern World
Dr Michael VARNEY
GENENTECH, South San Francisco, United States
Synthesis of Fluorine Containing Amino Acids with Biological Interest
Prof. Valery P. KUKHAR
INSTITUTE OF BIOORGANIC CHEMISTRY AND PETROCHEMISTRY, Kyiv, Ukraine
Building Molecular Complexity via Gold Catalysis
Prof. Antonio M. ECHAVARREN
INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA (ICIQ), Tarragona, Spain
Coffee-break
The Discovery of the Oral Antifungal Agent Albaconazole: a Case History
Dr. Xavi BARTROLI
PALAU PHARMA, Palau de Plegamans, Spain
New Catalytic Strategies for Chemical Synthesis
Prof. Matthew GAUNT
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Closing Remarks
Symposium banquet